查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
利用真實世界證據 (RWE) 協助製藥產業取得策略優勢
市場調查報告書
商品編碼
1776188

利用真實世界證據 (RWE) 協助製藥產業取得策略優勢

Harnessing Real-World Evidence for Strategic Advantage in Pharma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入探討了真實世界證據 (RWE) 在藥物生命週期中的策略整合，重點關注其從補充資料來源到決策關鍵推動因素的演變。報告探討了監管機構對 RWE 日益增長的接受度、其在衛生技術評估中的作用以及其對市場准入和報銷策略的影響。報告還探討了上市後監管的課題、對建立緊密結合的數據生態系統的需求，以及人工智慧 (AI) 在 RWE 生成方面的變革潛力。建立強大的 RWE 能力並將證據與付款人需求相結合，可以提供有助於推動策略成果的洞察。

關鍵問題解答

  • 1.藥廠如何利用真實世界證據 (RWE) 協助取得策略優勢？
  • 2.RWE 在製藥業中的戰略重要性是什麼？
  • 3.如何在監理申報中有效利用 RWE？
  • 4.RWE 如何影響健康科技評估 (HTIA)？
  • 5.RWE 如何增強市場進入與報銷策略？
  • 6.RWE 在上市後監理中扮演什麼角色？
  • 7.建構強大 RWE 能力的最佳實踐是什麼？
  • 8.分析方法的進步如何改變 RWE 的生成？
  • 9.企業必須克服哪些課題才能將 RWE 納入製藥策略？
  • 10.企業如何將 RWE 與付款人需求結合，以打開市場准入的大門？

主要企業

  • UCB
  • LEO Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Flatiron Health
  • Apple
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Aetion

部分參加專家名單

  • 比利時優時比（UCB）RWE免疫學負責人
  • 全球製藥公司臨床策略與證據生成副總監
  • 丹麥利奧製藥（LEO Pharma）全球策略、證據與傳播負責人
  • 德國阿斯特捷利康（AstraZeneca）醫療與法規事務副總裁
  • 德國勃林格殷格翰（Boehringer Ingelheim）全球臨床營運總監
  • 英國優時比（UCB）副總裁、全球RWE與數位科學負責人

方法論：

檔案報告是基於獨立而簡潔的分析，這些分析源自於專有的產業研究以及與產業思想領袖的深入訪談。這些報告深入分析了製藥企業高階主管需要了解的關鍵趨勢和市場發展，以應對未來的機會和課題。每份報告的重點都基於對二手文獻的回顧和已發現的知識差距。基於這些初步研究，我們制定了基於證據的討論指南，並結合專家意見，以確保研究能夠解答最重要的問題。此外，我們採用嚴格的篩選標準，以確保受訪者擁有相應的經驗、知識和發言資格。

我們的報告有何獨特之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助我們的客戶掌握新興趨勢並有效解決複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家專訪和數據，以及持續的市場監測，確保您全面了解市場動態。我們的報告涵蓋 40 多個活躍疾病領域，包含 KOL 洞察和定量醫生調查等醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入及其他領域問題的看法，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

This report delves into the strategic integration of real-world evidence (RWE) across the pharmaceutical lifecycle, highlighting its evolution from a supplementary data source to a critical driver of decision-making. It examines the growing regulatory acceptance of RWE, its role in health technology assessments and its impact on market access and reimbursement strategies. The report also addresses the challenges of post-marketing surveillance, the need for cohesive data ecosystems and the transformative potential of AI in RWE generation. Gain insights into building robust RWE capabilities and aligning evidence with payer needs to enhance strategic outcomes.

Key Questions Answered:

  • 1. How can pharmaceutical companies leverage real-world evidence (RWE) for strategic advantage?
  • 2. What is the strategic importance of RWE in the pharmaceutical industry?
  • 3. How can RWE be effectively used in regulatory submissions?
  • 4. In what ways does RWE influence health technology assessments?
  • 5. How does RWE enhance market access and reimbursement strategies?
  • 6. What role does RWE play in post-marketing surveillance?
  • 7. What are the best practices for building robust RWE capabilities?
  • 8. How are advances in analytical methods transforming RWE generation?
  • 9. What challenges must be overcome to integrate RWE into pharma strategy?
  • 10. How can companies align RWE with payer needs to unlock market access?

Key Companies:

  • UCB
  • LEO Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Flatiron Health
  • Apple
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Aetion

Partial List of Participating Experts:

  • Head of RWE Immunology, UCB, Belgium
  • Associate Director, Clinical Strategy and Evidence Generation, global pharma company
  • Head of Global Strategic Evidence and Communications, LEO Pharma, Denmark
  • VP Medical & Regulatory, AstraZeneca, Germany
  • Global Head Clinical Practice, Boehringer Ingelheim, Germany
  • Vice President, Head of Global RWE and Digital Sciences, UCB, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.